<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004363</url>
  </required_header>
  <id_info>
    <org_study_id>NCRR-M01RR00048-0568</org_study_id>
    <secondary_id>NU-568</secondary_id>
    <nct_id>NCT00004363</nct_id>
  </id_info>
  <brief_title>Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II&#xD;
      (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by&#xD;
      directing the production of an abnormal preprohormone.&#xD;
&#xD;
      II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys&#xD;
      magnocellular neurons because it cannot be folded and processed efficiently.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This project involves 2 clinical studies. Members of known kindreds&#xD;
      participate in Study I; members of kindreds who have not been surveyed, genotyped, or&#xD;
      phenotyped participate in Study II.&#xD;
&#xD;
      In Study I, participants undergo clinical, hormonal, radiologic, and biochemical studies.&#xD;
      Assessment on unrestricted fluid intake includes body weight, urine volume, osmolality,&#xD;
      creatinine, sodium, potassium, urea, glucose, arginine-vasopressin (AVP), oxytocin, and&#xD;
      aquaporin-II.&#xD;
&#xD;
      Participants with diabetes insipidus (DI) undergo a standard fluid deprivation test; those&#xD;
      without DI undergo standard water load and hypertonic saline testing.&#xD;
&#xD;
      Previously untreated DI patients may be given intranasal or subcutaneous desmopressin or oral&#xD;
      chlorpropamide (adults only) for 2 or 3 days.&#xD;
&#xD;
      Magnetic resonance imaging of the pituitary-hypothalamic area is performed on all patients&#xD;
      with and without gadolinium.&#xD;
&#xD;
      Infants and children are studied annually for the first 5 years or until they develop DI.&#xD;
      Affected adults are studied every 2-5 years. Unaffected adults are re-tested only if they&#xD;
      subsequently report de novo symptoms suggestive of DI.&#xD;
&#xD;
      In Study II, participants undergo similar genotype and phenotype testing. Kindreds&#xD;
      demonstrating the familial neurohypophyseal diabetes insipidus phenotype and genotype are&#xD;
      added to Study I. Kindreds found to have a different type of DI are directed into a companion&#xD;
      protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1995</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Diabetes Insipidus</condition>
  <condition>Diabetes Insipidus, Neurohypophyseal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorpropamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desmopressin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Verified or suspected familial neurohypophyseal diabetes insipidus with or without an&#xD;
             identified mutation of the vasopressin-neurophysin II gene Affected and unaffected&#xD;
             members of kindreds entered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary L. Robertson</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen LK, Rittig S, Robertson GL. Genetic basis of familial neurohypophyseal diabetes insipidus. Trends Endocrinol Metab. 1997 Nov;8(9):363-72. doi: 10.1016/s1043-2760(97)00157-4.</citation>
    <PMID>18406826</PMID>
  </reference>
  <reference>
    <citation>Rittig S, Robertson GL, Siggaard C, Kovacs L, Gregersen N, Nyborg J, Pedersen EB. Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Am J Hum Genet. 1996 Jan;58(1):107-17.</citation>
    <PMID>8554046</PMID>
  </reference>
  <reference>
    <citation>McLeod JF, Kovacs L, Gaskill MB, Rittig S, Bradley GS, Robertson GL. Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation. J Clin Endocrinol Metab. 1993 Sep;77(3):599A-599G. doi: 10.1210/jcem.77.3.8370682.</citation>
    <PMID>8370682</PMID>
  </reference>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>diabetes insipidus</keyword>
  <keyword>endocrine disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Diabetes Insipidus, Neurogenic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorpropamide</mesh_term>
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

